Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medexus Pharmaceuticals Inc (MEDXF)

Medexus Pharmaceuticals Inc (MEDXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®....

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus Announces Fiscal Q3 2024 Results

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto,...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus Schedules Third Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday,...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus Schedules Second Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

All director nominees reelected and all other company proposals approved by shareholdersToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP)...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)
Medexus Strengthens Balance Sheet with US$18 Million Commitment Under Accordion Facility

Medexus expects net proceeds, together with projected cash on hand, to fully satisfy convertible debentures in cash at maturity in October 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. -...

MEDXF : 1.1700 (-1.68%)
MDP.TO : 1.60 (-1.23%)

Barchart Exclusives

Up 33% YTD, This Energy Dividend Stock Is Still a Top Offshore Pick
Discover why TechnipFMC has become Barclays' top offshore pick, and how its impressive performance and strategic advantages make it a standout dividend stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar